<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H8C02CA3A8EE1483FA9CDDE98DE1A5ADF" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 3375 IH: Support, Treatment, and Overdoses Prevention of Fentanyl Overdoses Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-05-16</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 3375</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230516">May 16, 2023</action-date><action-desc><sponsor name-id="K000382">Ms. Kuster</sponsor> (for herself, <cosponsor name-id="B001303">Ms. Blunt Rochester</cosponsor>, <cosponsor name-id="B001298">Mr. Bacon</cosponsor>, <cosponsor name-id="T000469">Mr. Tonko</cosponsor>, <cosponsor name-id="T000483">Mr. Trone</cosponsor>, <cosponsor name-id="P000613">Mr. Panetta</cosponsor>, <cosponsor name-id="T000482">Mrs. Trahan</cosponsor>, <cosponsor name-id="A000376">Mr. Allred</cosponsor>, <cosponsor name-id="C001119">Ms. Craig</cosponsor>, <cosponsor name-id="P000620">Ms. Pettersen</cosponsor>, <cosponsor name-id="B001300">Ms. Barragán</cosponsor>, and <cosponsor name-id="N000188">Mr. Norcross</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To establish programs to address addiction and overdoses caused by illicit fentanyl and other opioids, and for other purposes.</official-title></form><legis-body id="H84B8D4D83D4045E0BD2AFC26B95A8A22" style="OLC"><section id="H8CBCFBAB922F46ECAFCEB5719BE6E61A" section-type="section-one"><enum>1.</enum><header>Short title; table of contents</header><subsection id="H8A34465267BD4370A62D6A5C9738C0B2"><enum>(a)</enum><header>Short title</header><text>This Act may be cited as the <quote><short-title>Support, Treatment, and Overdoses Prevention of Fentanyl Overdoses Act of 2023</short-title></quote> or the <quote><short-title>STOP Fentanyl Overdoses Act of 2023</short-title></quote>.</text></subsection><subsection id="H912A9A74B286453DADEF5E50DFA564A8"><enum>(b)</enum><header>Table of contents</header><text>The table of contents for this Act is as follows:</text><toc container-level="legis-body-container" quoted-block="no-quoted-block" lowest-level="section" regeneration="yes-regeneration" lowest-bolded-level="division-lowest-bolded"><toc-entry idref="H8CBCFBAB922F46ECAFCEB5719BE6E61A" level="section">Sec. 1. Short title; table of contents.</toc-entry><toc-entry idref="HBDC25064A53D4F9F97BBA256E342733D" level="section">Sec. 2. Definitions.</toc-entry><toc-entry idref="H75AA17AA2D2245D485898891F987B218" level="title">Title I—Improving Fentanyl Surveillance</toc-entry><toc-entry idref="H0963A3A80E694EBFA9FF225F96372A32" level="section">Sec. 101. Enhanced drug surveillance.</toc-entry><toc-entry idref="HF10248F13E124AF7AB0CEB830900E320" level="section">Sec. 102. Collection of overdose data.</toc-entry><toc-entry idref="HC07E4AC07540451BBEFBA9462158E3BD" level="section">Sec. 103. Public health support for law enforcement.</toc-entry><toc-entry idref="HFB9B40ACB01445E192DB93CC59FE7683" level="section">Sec. 104. Fentanyl detection.</toc-entry><toc-entry idref="H1C1D62F1A40447D9AD996ABA753EE913" level="section">Sec. 105. Grants to improve public health surveillance in forensic laboratories.</toc-entry><toc-entry idref="H4CC3780285F949E99B95C06ECEF119E4" level="title">Title II—Stemming the Supply of Fentanyl</toc-entry><toc-entry idref="H9665C4CB07244636AC963F055345C764" level="section">Sec. 201. Report on countries that produce synthetic drugs.</toc-entry><toc-entry idref="H21E6ADB791CF4673ADE013418B35684B" level="section">Sec. 202. GAO report on international mail and cargo screening.</toc-entry><toc-entry idref="HAD54439D51DE40128A76C80D513EA294" level="title">Title III—Overdose Prevention and Substance Use Disorder Treatment Programs</toc-entry><toc-entry idref="H1BC4C9DEA9C240978BB202279DD09FC6" level="section">Sec. 301. Opioid treatment education.</toc-entry><toc-entry idref="H59F5DBC80CEE40D09AC0F2C169E2AC8D" level="section">Sec. 302. Study on naloxone access.</toc-entry><toc-entry idref="HFCBB99E78AC741B3B45E667C0916FA29" level="section">Sec. 303. Increasing access to medication for opioid overdose reversal.</toc-entry><toc-entry idref="HA61A38B6BA0E47CAA05E3DDB26A0087A" level="section">Sec. 304. Grant program on harms of drug misuse.</toc-entry><toc-entry idref="HF696D5557E014ABC821AA224530EA153" level="section">Sec. 305. Good Samaritan immunity.</toc-entry><toc-entry idref="H914258B822544A6888102F2024531CEB" level="section">Sec. 306. Report on overdose prevention centers.</toc-entry><toc-entry idref="H13E34531798D4DD9A465A6B5E59E95C5" level="section">Sec. 307. Prisons and substance use disorder treatment.</toc-entry></toc></subsection></section><section id="HBDC25064A53D4F9F97BBA256E342733D"><enum>2.</enum><header>Definitions</header><text display-inline="no-display-inline">In this Act, except as otherwise provided:</text><paragraph id="H70A22865B9D44407AF3242B1509CE867"><enum>(1)</enum><text>The term <term>Assistant Secretary</term> means the Assistant Secretary for Mental Health and Substance Use.</text></paragraph><paragraph id="H91F577802497451E944283E30A8266B0"><enum>(2)</enum><text>The term <term>Secretary</term> means the Secretary of Health and Human Services.</text></paragraph><paragraph id="H1A14E3AB73164ED2B6C693EA5216106E"><enum>(3)</enum><text display-inline="yes-display-inline">The term <term>fentanyl-related substance</term> has the meaning given the term in section 1308.11(h)(30)(i) of title 21, Code of Federal Regulations (or successor regulations).</text></paragraph></section><title id="H75AA17AA2D2245D485898891F987B218"><enum>I</enum><header>Improving Fentanyl Surveillance</header><section id="H0963A3A80E694EBFA9FF225F96372A32"><enum>101.</enum><header>Enhanced drug surveillance</header><subsection id="H2AB01D72E4954473A544555206623F46"><enum>(a)</enum><header>CDC surveillance program</header><text display-inline="yes-display-inline">Title III of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/241">42 U.S.C. 241 et seq.</external-xref>) is amended by inserting after section 317V of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247b-24">42 U.S.C. 247b–24</external-xref>) the following:</text><quoted-block style="OLC" id="H56A2FBD4FBAE4D949A1872CD5F771D96" display-inline="no-display-inline"><section id="H0C5A0995F1634CAD8B9E9FB06994D3B8"><enum>317W.</enum><header>Enhanced drug surveillance</header><subsection id="H7E65E04EA5774D79AEF711728ACC74D4"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall enhance the Overdose Data to Action drug surveillance program of the Centers and other drug surveillance programs by—</text><paragraph id="HDCE8EB55F5E046B48CF82F0C43B8F8D7"><enum>(1)</enum><text display-inline="yes-display-inline">encouraging States, political subdivisions of States, and territories to participate;</text></paragraph><paragraph id="H14CAB67F3FA645CCB9B25B241ECBE71F"><enum>(2)</enum><text display-inline="yes-display-inline">increasing and accelerating the collection of data on fentanyl, fentanyl-related substances, other synthetic opioids, and new emerging drugs of use (including harmful adulterants of fentanyl such as xylazine), including the collection of related overdose data from medical examiners and drug treatment admissions and information regarding drug seizures; and</text></paragraph><paragraph id="H27EA6A947B3A4064B5EEDD744EFACE02"><enum>(3)</enum><text display-inline="yes-display-inline">utilizing available and emerging information on fentanyl, fentanyl-related substances, other synthetic opioids, and new emerging drugs of abuse, including information from—</text><subparagraph id="H60ED0A2A49804E468CCB028E1C18D620"><enum>(A)</enum><text display-inline="yes-display-inline">the High Intensity Drug Trafficking Areas program; </text></subparagraph><subparagraph id="H15B9EE0CBA4F4E478C8B2C7AAC51AE73"><enum>(B)</enum><text>the National Drug Early Warning System;</text></subparagraph><subparagraph id="HAB69432933FD4D919E638FC6385D4A15"><enum>(C)</enum><text>State and local public health authorities;</text></subparagraph><subparagraph id="H8C68AD4094884188BA6CA0AA6EE63500"><enum>(D)</enum><text>Federal, State, and local public health laboratories; and</text></subparagraph><subparagraph id="HFFA0E5DE3B4040CFB5E1B497C76ED60B"><enum>(E)</enum><text>drug seizures by Federal, State, and local law enforcement agencies, including information from the National Seizure System and the National Forensic Laboratory Information System of the Drug Enforcement Administration.</text></subparagraph></paragraph></subsection><subsection id="H7D1093098C954310B0B35F4F2C933C63"><enum>(b)</enum><header>Information sharing</header><text display-inline="yes-display-inline">The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall publicly disseminate findings collected through the Overdose Data to Action drug surveillance program of the Centers for Disease Control and Prevention.</text></subsection><subsection id="HE6C038497B344276BB618EFE8C8C6790"><enum>(c)</enum><header>Definition</header><text display-inline="yes-display-inline">In this section, the term <term>fentanyl-related substance</term> has the meaning given the term in section 1308.11(h)(30)(i) of title 21, Code of Federal Regulations (or successor regulations).</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H0926A9FAFDA34DE38CCB4638F1CB4AF1"><enum>(b)</enum><header>Law enforcement reporting</header><text>Each Federal law enforcement agency shall report information on all drug seizures by that agency to the Drug Enforcement Administration for inclusion in the National Seizure System.</text></subsection><subsection id="H7F3262D304A3401E8F0F7865D5898DDF"><enum>(c)</enum><header>GAO report</header><text>Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall—</text><paragraph id="H6844DFA4EC07471E8C15F00C7B69E1BA"><enum>(1)</enum><text>publish a report analyzing how Federal agencies can improve their collection, reporting, sharing, and analytic use of drug seizure data across Federal agencies and with State and local governments; and</text></paragraph><paragraph id="HF48813F477294B15AFA151F001943C01"><enum>(2)</enum><text>include in such report an analysis of how well available data on drug seizures can measure progress toward reducing drug trafficking into and within the country, as outlined in strategies such as the National Drug Control Strategy of the Office of National Drug Control Policy.</text></paragraph></subsection></section><section id="HF10248F13E124AF7AB0CEB830900E320" commented="no"><enum>102.</enum><header>Collection of overdose data</header><subsection id="H6F9C073EFBB2484D983142D0C646633F" commented="no"><enum>(a)</enum><header>In general</header><text>Not later than 2 years after the date of enactment of this Act, the Secretary shall commence a study on how to most efficiently track overdoses by type of drug, including fentanyl.</text></subsection><subsection id="HDD081BE41E4140368CC9C1331681612A" commented="no"><enum>(b)</enum><header>Grant program</header><paragraph id="HBFA4DF0B5F0E4BBD9063B08D0147F30E" commented="no"><enum>(1)</enum><header>In general</header><text>Upon completion of the study under subsection (a), and taking into consideration the results of such study, the Secretary shall award grants to States to facilitate the collection of data with respect to fentanyl-involved overdoses.</text></paragraph><paragraph id="H56141EAFCC374BECB5F87FB16A6FF14E"><enum>(2)</enum><header>Requirement</header><text>As a condition on receipt of a grant under this subsection, an applicant shall agree to share the data collected pursuant to the grant with the Centers for Disease Control and Prevention.</text></paragraph><paragraph id="H5F1D9468C73C420F85D8A3E3945AEC40" commented="no"><enum>(3)</enum><header>Preference</header><text>In awarding grants under this subsection, the Secretary shall give preference to applicants whose grant proposals demonstrate the greatest need for collecting timely and accurate data on overdoses.</text></paragraph></subsection></section><section id="HC07E4AC07540451BBEFBA9462158E3BD"><enum>103.</enum><header>Public health support for law enforcement</header><subsection id="H646C66FE2FBD4F70B26CDCE00F5234C8"><enum>(a)</enum><header>Support for fentanyl detection and handling</header><text display-inline="yes-display-inline">The Secretary, in consultation with the Attorney General, shall carry out a program to provide to Federal, State, and local law enforcement agencies training on accurate information about fentanyl and how to detect and handle fentanyl.</text></subsection><subsection id="HAB0DCBA6024F4EC2922F3F94BB417009"><enum>(b)</enum><header>Evidence-Based</header><text>The program under subsection (a) shall comply with evidence-based guidelines, including the <quote>Fentanyl Safety Recommendations for First Responders</quote> (or any successor guidelines) of the Office of National Drug Control Policy.</text></subsection></section><section id="HFB9B40ACB01445E192DB93CC59FE7683" commented="no"><enum>104.</enum><header>Fentanyl detection</header><subsection id="H25C2D9E52EE443E59A08CA2A19DA4408" commented="no"><enum>(a)</enum><header>Testing of contaminants</header><text display-inline="yes-display-inline">The Secretary, acting through the Assistant Secretary and in coordination with the Director of the Centers for Disease Control and Prevention, shall continue to improve efforts to enhance screening and identification of contaminants in drugs to prevent overdoses.</text></subsection><subsection id="HE348FA438FFF4E10AC75474A6B58A232" commented="no"><enum>(b)</enum><header>Research into technologies</header><text display-inline="yes-display-inline">The Secretary shall conduct or support research for the development or improvement of portable and affordable technologies related to checking drugs for fentanyl and fentanyl-related substances, including chemical screening device methods.</text></subsection></section><section id="H1C1D62F1A40447D9AD996ABA753EE913" commented="no"><enum>105.</enum><header>Grants to improve public health surveillance in forensic laboratories</header><text display-inline="no-display-inline">Title I of the Omnibus Crime Control and Safe Streets Act of 1968 (<external-xref legal-doc="usc" parsable-cite="usc/34/10101">34 U.S.C. 10101 et seq.</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="H5200091751604751BFB2BF5C57DDAFAC" display-inline="no-display-inline"><part id="HDA94FDF6B10E4EEA825CC3B7C95F4D82" commented="no"><enum>PP</enum><header>Confronting the use of heroin, fentanyl, and associated synthetic drugs</header><section id="H224523DFDC2742BCB0AAD2C498BDA7E9" commented="no"><enum>3061.</enum><header>Grants to address public safety through improved forensic laboratory data</header><subsection id="H2AD0DA722C3A428E9D54F9A2383B5017"><enum>(a)</enum><header>Purpose</header><text display-inline="yes-display-inline">The purpose of a grant awarded under this section shall be to promote public health by assisting a State or unit of local government—</text><paragraph id="HE0931920EC194A31A19594A7AADE987C"><enum>(1)</enum><text display-inline="yes-display-inline">establish or improve a surveillance program in order to facilitate the seizure of covered controlled substances; and </text></paragraph><paragraph id="H34FCECC3F7BD42288561168DCDA3E804"><enum>(2)</enum><text>carry out the activities described in section 101 of the <short-title>STOP Fentanyl Overdoses Act of 2023</short-title>.</text></paragraph></subsection><subsection id="H527743A0BD4E4983B5142CA3E086B3CE" commented="no"><enum>(b)</enum><header>Establishment of grant</header><text display-inline="yes-display-inline">The Attorney General, acting through the Director of the Bureau of Justice Assistance, may make a grant to a State or unit of local government to promote public health by establishing or improving a surveillance program in order to facilitate the seizure of covered controlled substances. </text></subsection><subsection id="H7D28A969C1634C38B0F3045D30EC7A09" commented="no"><enum>(c)</enum><header>Eligible projects</header><text> A grant awarded under this section shall be used for a program, project, or other activity to—</text><paragraph id="H875B7F6BB5824C118044E7411DC3AE91" commented="no"><enum>(1)</enum><text>reimburse a State, local, or other forensic science laboratory for costs associated with testing to help address any backlog of untested samples of covered controlled substances;</text></paragraph><paragraph id="H8EEFAD5C55244C909C6A6B5BC7237A5C" commented="no"><enum>(2)</enum><text>reimburse a State, local, or other forensic science laboratory for the procurement of equipment, technology, or other support systems;</text></paragraph><paragraph id="H6916F021E0D34A54AEF6A9453DE8E4A2" commented="no"><enum>(3)</enum><text display-inline="yes-display-inline">reimburse State, local, or other forensic science laboratory for improved, real time data exchange with the Centers for Disease Control and Prevention on covered controlled substances; and</text></paragraph><paragraph id="HDBADC7F4B39041B1913D445CCFA8A19B" commented="no"><enum>(4)</enum><text display-inline="yes-display-inline">support a State or local health departments deployed to address the use of covered controlled substances.</text></paragraph></subsection><subsection id="H90A5A1DF92674348B47F117BD1920157"><enum>(d)</enum><header>Additional requirement</header><text display-inline="yes-display-inline">A program, project, or other activity pursuant to subsection (c)(2) shall require that the State, unit of local government, or Tribe demonstrate, to the satisfaction of the Attorney General, that any reimbursement would result in improved efficiency of laboratory testing and help prevent future backlogs. </text></subsection><subsection id="H5EF9BF3BF8594038AA060546B093EF59" commented="no"><enum>(e)</enum><header>Allocation</header><paragraph id="H9FE6B639C62941D18603D350899169FF" commented="no"><enum>(1)</enum><header>Population allocation</header><text>Seventy-five percent of the amount made available to carry out this section in a fiscal year shall be allocated to each State or unit of local government that meets the requirements of section 2802 so that each State or unit of local government shall receive an amount that bears the same ratio to the 75 percent of the total amount made available to carry out this section for that fiscal year as the population of the State or unit of local government bears to the population of all States or units of local governments. </text></paragraph><paragraph id="H32B52AFF8443414F826DECD64D2E5D43" commented="no"><enum>(2)</enum><header>Discretionary allocation</header><text display-inline="yes-display-inline">Twenty-five percent of the amount made available to carry out this section in a fiscal year shall be allocated pursuant to the discretion of the Attorney General for competitive grants to States or units of local government with high rates of primary treatment admissions for polysubstance use, including for covered controlled substances, for use by State, local, or Tribal law enforcement agencies.</text></paragraph><paragraph id="H710519DE2C4B4DE08510ABA9E01B38CA"><enum>(3)</enum><header>Limitation</header><text>Not less than 60 percent of any amounts made available to carry out this section shall be awarded for a program, project, or other activity under paragraph (1) or (2) of subsection (c).</text></paragraph><paragraph id="HBA395A1D1F9F4A959223578136B5DB56" commented="no"><enum>(4)</enum><header>Minimum requirement</header><text>Notwithstanding paragraphs (1), (2), and (3), each State receiving funds shall not receive less than 0.6 percent of the amount made available to carry out this section in each fiscal year.</text></paragraph></subsection><subsection id="H0BD5651398BA45CDA86101DEDF66D708"><enum>(f)</enum><header>Covered controlled substance defined</header><text display-inline="yes-display-inline">In this section, the term <term>covered controlled substance</term> means heroin, fentanyl, a fentanyl-related substance, and any associated synthetic drug. </text></subsection></section></part><after-quoted-block>.</after-quoted-block></quoted-block></section></title><title id="H4CC3780285F949E99B95C06ECEF119E4"><enum>II</enum><header>Stemming the Supply of Fentanyl</header><section id="H9665C4CB07244636AC963F055345C764"><enum>201.</enum><header>Report on countries that produce synthetic drugs</header><text display-inline="no-display-inline"> Not later than one year after the date of enactment of this Act, the Secretary of State shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on the Judiciary of the Senate a report— </text><paragraph id="H4041BB49430E44F3B67437C67CA1C064"><enum>(1)</enum><text>identifying the countries the Secretary determines are the principal producers of synthetic drugs trafficked into the United States;</text></paragraph><paragraph id="H985C0AEA65924192A37682B14E4FE807"><enum>(2)</enum><text>assessing how and why those countries are producing such drugs; and</text></paragraph><paragraph id="H771237F38F8B4474A0F385AD122CB559"><enum>(3)</enum><text>describing measures the Secretary plans to take to reduce the flow of such drugs into the United States.</text></paragraph></section><section id="H21E6ADB791CF4673ADE013418B35684B"><enum>202.</enum><header>GAO report on international mail and cargo screening</header><text display-inline="no-display-inline">Not later than one year after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Congress a report reviewing the impact of High Intensity Drug Trafficking Areas program on illicit fentanyl and fentanyl-related substances imported through international mail and cargo, including discussion of the following:</text><paragraph id="H3FE49D7B13B344C48D2F1F71E2E68E42"><enum>(1)</enum><text display-inline="yes-display-inline">The volume of fentanyl and fentanyl-related substances being imported into the country by means of international mail and cargo.</text></paragraph><paragraph id="H6A713118F10A4E0E850F7B25AD51CAEE"><enum>(2)</enum><text>The potential impact of increased screening for illicit fentanyl and fentanyl-related substances on—</text><subparagraph id="HC411B2D8CC1845ABBE2F8BB4CD9863C5"><enum>(A)</enum><text>deterring drug trafficking in the United States;</text></subparagraph><subparagraph id="HBCBA5E3CC09A43E2BD1F22C70DD81DF5"><enum>(B)</enum><text display-inline="yes-display-inline">interdicting fentanyl and fentanyl-related substances that were manufactured outside of the United States and intended, or attempted, to be imported into the United States;</text></subparagraph><subparagraph id="H244955FC7A044089A5654EFF0F29EEF8"><enum>(C)</enum><text display-inline="yes-display-inline">the number of Federal criminal prosecutions based on the manufacture, distribution, or possession of fentanyl or fentanyl-related substances, disaggregated by demographic data, including sex, race, and ethnicity, of the offender;</text></subparagraph><subparagraph id="HDA0EDCD013054708BBE0016568B453C2"><enum>(D)</enum><text>the charges brought in such prosecutions;</text></subparagraph><subparagraph id="HBCC1DC5AD5BD459ABE46444413672944"><enum>(E)</enum><text>the impacts of prosecutions on reducing demand and availability to users; and</text></subparagraph><subparagraph id="H8E81E3AFE9034BBAB562B8B657D1C07B"><enum>(F)</enum><text display-inline="yes-display-inline">the development of new fentanyl-related substances.</text></subparagraph></paragraph><paragraph id="HFD9F808858124985878E952EBC604E7D"><enum>(3)</enum><text>The need for non-invasive technology in screening for fentanyl and fentanyl-related substances, taking into account the findings pursuant to paragraphs (1) and (2).</text></paragraph></section></title><title id="HAD54439D51DE40128A76C80D513EA294"><enum>III</enum><header>Overdose Prevention and Substance Use Disorder Treatment Programs</header><section id="H1BC4C9DEA9C240978BB202279DD09FC6"><enum>301.</enum><header>Opioid treatment education</header><text display-inline="no-display-inline">Part D of title V of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290dd">42 U.S.C. 290dd et seq.</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="HEB9CF17C04424EE394C4CDA6C7CF99F7" display-inline="no-display-inline"><section id="HECA4D949E83444C085462323FECDFB88"><enum>553.</enum><header>Opioid treatment education</header><subsection id="HAC529E7DBCDE42FABDC7CF5CC9FE65F5"><enum>(a)</enum><header>In general</header><text>The Secretary shall award grants to States and local governmental entities to provide education to stakeholders, including health care providers, criminal justice professionals, and substance use disorder treatment personnel, on the current state of research on treatment for opioid use disorder, including—</text><paragraph id="HCBD65003963A491A936FF88C0E9903CE"><enum>(1)</enum><text>the use of opioid agonists or partial agonists; and</text></paragraph><paragraph id="H680ABB259DFF4648AE909F8D25693711"><enum>(2)</enum><text>the potential benefits of the use of opioid agonists or partial agonists for affected individuals.</text></paragraph></subsection><subsection id="H9CA5B817EAFC44F4A118E71F8B869A7E"><enum>(b)</enum><header>Report</header><text display-inline="yes-display-inline">Not later than one year after the date of enactment of the <short-title>STOP Fentanyl Overdoses Act of 2023</short-title>, the Secretary shall submit a report to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate, including the following data:</text><paragraph id="H748DE0C2F0D74D89B1430C5C2117856A"><enum>(1)</enum><text display-inline="yes-display-inline">The number of people reached by educational materials funded pursuant to this section.</text></paragraph><paragraph id="HFBE1EF99B51E4A819286370E0B32EE6D"><enum>(2)</enum><text display-inline="yes-display-inline">The geographic areas where people received such educational materials.</text></paragraph><paragraph id="H4A5C7E799E524B77992288C52CA52213"><enum>(3)</enum><text display-inline="yes-display-inline">The remaining populations and areas targeted for awareness of educational materials, including the characteristics of such populations and areas such as the type of stakeholder and geographic area.</text></paragraph><paragraph id="H337B856BCD534F06B40565A6E75F68BA"><enum>(4)</enum><text display-inline="yes-display-inline">The select outcomes of education funded pursuant to this section as determined by the Secretary.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section><section id="H59F5DBC80CEE40D09AC0F2C169E2AC8D"><enum>302.</enum><header>Study on naloxone access</header><subsection id="HBC4D55800B1B4FF28675DB882EA8FB9F"><enum>(a)</enum><header>In general</header><text>The Comptroller General of the United States shall conduct a study on actions that may be taken to ensure appropriate access and affordability of naloxone for individuals seeking to purchase naloxone. Such study shall address what is known about—</text><paragraph id="HD68A562AB80345889F19EA3191AC08AD"><enum>(1)</enum><text display-inline="yes-display-inline">coverage of naloxone (in any available form), including whether naloxone can be covered as an over-the-counter drug under a group health plan or group or individual health insurance coverage (as such terms are defined in section 2791 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300gg-91">42 U.S.C. 300gg–91</external-xref>)) or for individuals entitled to benefits under part A or enrolled under part B of title XVIII of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395">42 U.S.C. 1395 et seq.</external-xref>) or receiving medical assistance under a State plan under title XIX of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396">42 U.S.C. 1396 et seq.</external-xref>) or a waiver of such plan;</text></paragraph><paragraph id="H025AA1A3A59E4270A4A00EB42CB3A023"><enum>(2)</enum><text>the out-of-pocket cost to consumers purchasing naloxone—</text><subparagraph id="H10E6C5B474F24ED1AFF6B995180BE00F"><enum>(A)</enum><text>with a prescription, with and without coverage under any such plan or coverage;</text></subparagraph><subparagraph id="H3CF3545C4843452F940F6EC71874F330"><enum>(B)</enum><text>over-the-counter, with and without coverage under any such plan or coverage; and</text></subparagraph><subparagraph id="HDF935902F3F441518C71BC2A0144007A"><enum>(C)</enum><text>pursuant to a standing order; and</text></subparagraph></paragraph><paragraph id="H5EBDE96B03574A1B9736201B9D3BE5BC"><enum>(3)</enum><text>other factors impacting coverage, including barriers in covering naloxone as an over-the-counter drug, the relative net costs of naloxone when purchased over-the-counter without insurance coverage compared to when purchased with a prescription and covered under a group health plan or health insurance coverage, and the availability of naloxone purchased and distributed through public health entities.</text></paragraph></subsection><subsection id="H319EBA45C16141BFAFCB9DD1457F98AC"><enum>(b)</enum><header>Report</header><text>Not later than 2 years after the date of the enactment of this Act, the Comptroller General of the United States shall submit to Congress a report that contains the findings of the study conducted under subsection (a).</text></subsection></section><section id="HFCBB99E78AC741B3B45E667C0916FA29"><enum>303.</enum><header>Increasing access to medication for opioid overdose reversal</header><subsection id="H8AA67BABEC534F7597ED231CFE0FD17F"><enum>(a)</enum><header>Transactions</header><text>Section 581(24)(B) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360eee">21 U.S.C. 360eee(24)(B)</external-xref>) is amended—</text><paragraph id="H6717256418634A0D9014DA83F8670209"><enum>(1)</enum><text>by redesignating clauses (xvii) and (xviii) as clauses (xviii) and (xix), respectively; and</text></paragraph><paragraph id="HF3486D1088924A9DB448AE1A60DE67A9"><enum>(2)</enum><text>by inserting after clause (xvi) the following:</text><quoted-block id="H688E45CA1E154F23895042209A63E5FA" style="OLC"><clause id="H5B18D88B3F094C1F8F0BA1D4833833E2"><enum>(xvii)</enum><text>the distribution of an opioid antagonist indicated for emergency treatment of opioid overdose, such as naloxone, by or to an overdose prevention, syringe services program, or other harm reduction service;</text></clause><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H2170E1480B994494B49EF858BCC9A86C"><enum>(b)</enum><header>Wholesale distribution</header><text>Section 503(e)(4) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353">21 U.S.C. 353(e)(4)</external-xref>) is amended—</text><paragraph id="H7EC12F8B42E6452C8F42AC798626C4D3"><enum>(1)</enum><text>by redesignating subparagraphs (R) and (S) as subparagraphs (S) and (T), respectively; and</text></paragraph><paragraph id="HB1B8E4697272432D985D702F9BD04A65"><enum>(2)</enum><text>by inserting after subparagraph (Q) the following:</text><quoted-block id="H61948FFF6C0947EFB707106880425B8E" style="OLC"><subparagraph id="H0DD9B2EA12BA44E688E4742C51D7AB18"><enum>(R)</enum><text>the distribution of an opioid antagonist indicated for emergency treatment of opioid overdose, such as naloxone, by or to an overdose prevention, syringe services program, or other harm reduction service;</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection></section><section id="HA61A38B6BA0E47CAA05E3DDB26A0087A"><enum>304.</enum><header>Grant program on harms of drug misuse</header><text display-inline="no-display-inline">Part D of title V of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290dd">42 U.S.C. 290dd et seq.</external-xref>), as amended by section 301, is further amended by adding at the end the following:</text><quoted-block style="OLC" id="H18B528BE6A1C4AFAA3266F150141FD4F" display-inline="no-display-inline"><section id="H5982561E709B4992A0664797E8536414"><enum>554.</enum><header>Grant program on harms of drug misuse</header><subsection id="H6E24CD0CF4A141A6A03931EAE3A7C3B8"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Assistant Secretary, in consultation with the Director of the Centers for Disease Control and Prevention, shall award grants to States and political subdivisions of States to support the delivery of overdose prevention services, including distribution of Food and Drug Administration-approved opioid reversal agents such as naloxone, fentanyl strips, and other harm reduction services that address the harms of drug misuse, including by—</text><paragraph id="H4993DDF6CEF3460DA34BB4C4E4AF630C"><enum>(1)</enum><text display-inline="yes-display-inline">connecting individuals at risk for, or with, a substance use disorder to overdose education, counseling, and health education; and</text></paragraph><paragraph id="H3537779F222D4B7B8FED93036F4B5B46"><enum>(2)</enum><text>encouraging such individuals to take steps to reduce the harms associated with substance misuse.</text></paragraph></subsection><subsection id="HF5ABEBC08F414403816666336C78ADAC"><enum>(b)</enum><header>Considerations</header><text>In awarding grants under this section, the Assistant Secretary shall prioritize grants to applicants that are—</text><paragraph id="H3C66401A93FD42DB9750C30F1C30FEBA"><enum>(1)</enum><text display-inline="yes-display-inline">organizations providing culturally competent care in terms of considerations based on race, language, ethnicity, gender, sexuality, or disability; or</text></paragraph><paragraph id="HCFD8788F387049ECB1C405319A65DA43"><enum>(2)</enum><text>proposing to serve areas with—</text><subparagraph id="H9ECDA0FF6B2C4412BF3D6AC95C13B0E2"><enum>(A)</enum><text>a higher proportion of the population who meet criteria for dependence on, or abuse of, illicit drugs;</text></subparagraph><subparagraph id="H7B4AF5564B9B4B5AA7A51E37F13740E6"><enum>(B)</enum><text>a higher drug overdose death rate; and</text></subparagraph><subparagraph id="H9B4A3E7C2439427CBD85B73E21A246D9"><enum>(C)</enum><text>a greater behavioral health and substance use disorder workforce need.</text></subparagraph></paragraph></subsection><subsection id="H377CF8EA2F754BC89B0B583A5288DA9C"><enum>(c)</enum><header>Special considerations</header><text display-inline="yes-display-inline">A recipient of a grant under this section for the purposes described in subsection (a)(2) shall provide overdose prevention services, as follows:</text><paragraph id="H618748A354DE4938B8E6801EB1383DF4"><enum>(1)</enum><text display-inline="yes-display-inline">Ensure that not less than 60 percent of the grant funds are used for harm reduction programs.</text></paragraph><paragraph id="H07251D4654654C12B4293BB7C2C0F07D"><enum>(2)</enum><text display-inline="yes-display-inline">Prioritize the delivery of opioid antagonists to—</text><subparagraph id="HBA14C4013BD344FE8A097EBCEDBDE27D"><enum>(A)</enum><text display-inline="yes-display-inline">people who use opioids or illicit drugs;</text></subparagraph><subparagraph id="H2A88C5128CA84E3C925DE52508CD85BB"><enum>(B)</enum><text>families of such people;</text></subparagraph><subparagraph id="H74746923889C443088321CAD069DC59E"><enum>(C)</enum><text>first responders such as law enforcement personnel and nonemergency services such as fire fighters and park rangers; and</text></subparagraph><subparagraph id="H0E3A64CB71FD41BEBE98492BFB93ECB4"><enum>(D)</enum><text>community service providers, such as library, school, and public transportation personnel.</text></subparagraph></paragraph></subsection><subsection id="H9C7A288939204851BD2A4DF4D1F3ECAC"><enum>(d)</enum><header>Use of grant awards</header><text display-inline="yes-display-inline">A recipient of a grant under this section may use grant funds for the following:</text><paragraph id="HC1A091DFC0C247D3ABAE8DBECB6CB7ED"><enum>(1)</enum><text>Adapting, maintaining, and expanding essential services provided by harm reduction service organizations to address the risks of drug overdose and contraction of infectious disease.</text></paragraph><paragraph id="H2C1ECC97C4204DD4B1B81C330563E561"><enum>(2)</enum><text>Maintaining or hiring staff.</text></paragraph><paragraph id="H36850884F47540118B9ADA8B2F671D8C"><enum>(3)</enum><text>Supporting program operational costs, including staff, rent, and vehicle purchase or maintenance.</text></paragraph><paragraph id="H6B14DD8400534765AD7D6D3F068CA2C4"><enum>(4)</enum><text>Program supplies.</text></paragraph><paragraph id="H69C05E98BD3A438FADF20B79002653CE"><enum>(5)</enum><text>Support and case management services.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section><section id="HF696D5557E014ABC821AA224530EA153"><enum>305.</enum><header>Good Samaritan immunity</header><subsection id="HA390E8B82AE044A6855F1C59E1D72238"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Part B of title II of the Public Health Service Act is amended by inserting after section 248 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/238q">42 U.S.C. 238q</external-xref>) the following:</text><quoted-block style="OLC" id="HB98E72021E74463596F45435CEC21423" display-inline="no-display-inline"><section id="HF9CF43BA0188416E98C8986EBCF0C649"><enum>249.</enum><header>Good Samaritan immunity</header><subsection id="H4269908B30BC4D9E9597CA48D60F2801"><enum>(a)</enum><header>Limitation on civil liability for individuals who administer opioid overdose reversal drugs</header><paragraph id="HB137523BAD324685811DE0D4B7FBEBD2" commented="no"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Notwithstanding any other provision of law, except as provided in paragraph (2), no individual shall be liable in any Federal or State proceeding for harm caused by the emergency administration of an opioid overdose reversal drug to an individual who has or reasonably appears to have suffered an overdose from heroin or another opioid, if the individual who administers the opioid overdose reversal drug does so in good faith. </text></paragraph><paragraph id="HC8B733EE1FA944478804EF4E60998B46"><enum>(2)</enum><header>Exception</header><text>Paragraph (1) shall not apply to an individual if the harm was caused by the gross negligence or reckless misconduct of the individual who administers the drug.</text></paragraph><paragraph id="HC4BF8D332E414823AF86226281C7161D"><enum>(3)</enum><header>Definitions</header><text>In this subsection:</text><subparagraph id="HAB49628DC7F44AA098BFF6AEDFAE3CDE"><enum>(A)</enum><text display-inline="yes-display-inline">The term <term>health care professional</term> means a person licensed by a State to prescribe prescription drugs.</text></subparagraph><subparagraph id="HCD19A47EE15541C9B844C62E12233E72"><enum>(B)</enum><text display-inline="yes-display-inline">The term <term>opioid overdose reversal drug</term> means a drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act that is indicated for the partial or complete reversal of the pharmacological effects of an opioid overdose in the human body.</text></subparagraph><subparagraph id="H23090FEEFB154A4798397696E6F3F1EC"><enum>(C)</enum><text display-inline="yes-display-inline">The term <term>opioid overdose prevention program</term> means a program operated by a local health department, harm reduction or other community-based organization, substance abuse treatment organization, law enforcement agency, fire department, other first responder department, or voluntary association, or a program funded by a Federal, State, or local government, that works to prevent opioid overdoses by in part providing opioid overdose reversal drugs and education—</text><clause id="HB486A6C5F9D74C0C9828B245A7526FD5"><enum>(i)</enum><text>to individuals at risk of experiencing an opioid overdose; or</text></clause><clause id="H4314AEECDE594E088A6E8842860CE906"><enum>(ii)</enum><text>to an individual in a position to assist another individual at risk of experiencing an opioid overdose.</text></clause></subparagraph></paragraph></subsection><subsection id="HEA914D397FBB4F4FB3AC360393171C86" commented="no"><enum>(b)</enum><header>Immunity from liability</header><paragraph id="HB481078AB34048D082F8890E620A09A9" commented="no"><enum>(1)</enum><header>In general</header><text>An individual who, in good faith and in a timely manner—</text><subparagraph id="HB824826188CE4BDAA9BC608B44BE9EE4" commented="no"><enum>(A)</enum><text display-inline="yes-display-inline">seeks medical assistance for another individual who is experiencing a drug overdose, or</text></subparagraph><subparagraph id="HAF774A144A704CDB8EE349A89587EA27" commented="no"><enum>(B)</enum><text display-inline="yes-display-inline">seeks medical assistance for himself or herself for a drug overdose, or is the subject of a request for medical assistance described in subparagraph (A),</text></subparagraph><continuation-text continuation-text-level="paragraph" commented="no">shall not be cited, arrested, prosecuted, criminally liable, or subject to any sanction for a violation of a condition of supervised release under section 404 of the Controlled Substances Act for the possession or use of a controlled substance, or under any other provision of Federal law regulating the misuse of prescription drugs, as a result of seeking such medical assistance.</continuation-text></paragraph><paragraph id="H488266B3BBD041FFBC44A687D23097C3" commented="no"><enum>(2)</enum><header>Preemption</header><text display-inline="yes-display-inline">This subsection preempts the laws of a State or any political subdivision of a State to the extent that such laws are inconsistent with this section, unless such laws provide greater protection from liability.</text></paragraph><paragraph id="HE4F91C01BF5F4306934A6698D51C1B65" commented="no"><enum>(3)</enum><header>Definitions</header><text>In this section:</text><subparagraph id="H76B81137FFF248BB9BDA6BAE7BEC3D22" commented="no"><enum>(A)</enum><text>The term <term>controlled substance</term> has the meaning given the term in section 102 of the Controlled Substances Act.</text></subparagraph><subparagraph id="HB00C9D745A4F44329C7673BE6CBC1D57" commented="no"><enum>(B)</enum><text>The term <term>drug overdose</term> means an acute condition resulting from or believed to be resulting from the use of a controlled substance, which an individual, who is not a health care professional, would reasonably believe requires medical assistance.</text></subparagraph><subparagraph id="H86E7AE4816854C03856A3FEFF44FD6A5" commented="no"><enum>(C)</enum><text>The term <term>prescription drug</term> means a drug subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act. </text></subparagraph><subparagraph id="H48A0660EBA5144E6933D6ED19104765C" commented="no"><enum>(D)</enum><text>The terms <term>seeks medical assistance</term> and <term>seeking such medical assistance</term> include—</text><clause id="H348C92B265A448BE8DD3D74F95DE85A2" commented="no"><enum>(i)</enum><text>reporting a drug or alcohol overdose or other medical emergency to a law enforcement authority, the 9–1–1 system, a poison control center, or a medical provider;</text></clause><clause id="HC532A9A17E8D425EAAB3F9DC0C502571" commented="no"><enum>(ii)</enum><text>assisting another individual who is making a report described in clause (i); or</text></clause><clause id="H7C1A61D497934AECA3981BBDB28C6755" commented="no"><enum>(iii)</enum><text>providing care to someone who is experiencing a drug or alcohol overdose or other medical emergency while awaiting the arrival of medical assistance.</text></clause></subparagraph></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HF80A76BF5D02417CA1E9EA28A66E64AB" commented="no"><enum>(b)</enum><header>Public awareness campaign</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, in coordination with the Administrator of the Drug Enforcement Administration, shall carry out a campaign to increase public awareness of the limitations on civil and criminal liability established by section 249 of the Public Health Service Act, as added by subsection (a).</text></subsection></section><section id="H914258B822544A6888102F2024531CEB"><enum>306.</enum><header>Report on overdose prevention centers</header><text display-inline="no-display-inline">The Secretary of Health and Human Services shall enter into appropriate arrangements with the National Academies of Sciences, Engineering, and Medicine under which the Academies agree to—</text><paragraph id="H6E62FAE2B5E94544B303D81CEE792C95"><enum>(1)</enum><text display-inline="yes-display-inline">not later than two years after the date of enactment of this Act, submit to the Congress a report on overdose prevention centers; and</text></paragraph><paragraph id="HA3F0A61CDB2642C5ADAE4A0E596B3FF8"><enum>(2)</enum><text>include in such report—</text><subparagraph id="HFB07F0E6C0DC43548861C8EEDEA7A87B"><enum>(A)</enum><text display-inline="yes-display-inline">identification of barriers to operating overdose prevention centers; </text></subparagraph><subparagraph id="H090ADF3BDEAC4E30A6A9394849E7E197"><enum>(B)</enum><text>a compilation of the data available to measure effectiveness of overdose prevention centers on reducing overdose deaths, and improving access to medication for opioid use disorder and recovery services;</text></subparagraph><subparagraph id="H9EE4462DC6464154A3F2DEAF940AE27F"><enum>(C)</enum><text display-inline="yes-display-inline">identification of best practices to promote individual and community public health, provide resources to individuals and families, improve access to substance use disorder and behavioral health services, and reduce stigma;</text></subparagraph><subparagraph id="H9FB248A0F5D74A3B865B286FD45F6F05"><enum>(D)</enum><text>recommendations for developing integrated care settings inclusive of overdose prevention sites and incorporating overdose prevention sites into referral networks; and</text></subparagraph><subparagraph id="H124D366F1EED4D92854CE8A4C940E9D9"><enum>(E)</enum><text>approaches to overdose prevention services that may serve as effective strategies for recovery for people using fentanyl.</text></subparagraph></paragraph></section><section id="H13E34531798D4DD9A465A6B5E59E95C5" commented="no"><enum>307.</enum><header>Prisons and substance use disorder treatment</header><subsection id="HB9E033D684604AFD85FEFE7429FD8BF1" commented="no"><enum>(a)</enum><header>Prisons and medication-Assisted treatment</header><text display-inline="yes-display-inline">The Director of the Bureau of Prisons, in collaboration with the Director of the Office of National Drug Control Policy, shall establish a program to offer to individuals in the custody of the Bureau of Prisons—</text><paragraph id="HBEEF69816E4C42E7AC9442EA541C5108"><enum>(1)</enum><text>drugs that are approved by the Food and Drug Administration for treatment of a substance use disorder;</text></paragraph><paragraph id="HC97C2EEE0B724E68876FAD43FF57A846"><enum>(2)</enum><text>counseling and other psychosocial treatments for the treatment of substance use disorders; and</text></paragraph><paragraph id="HECAC7881A4714925B51836DB538C6A69"><enum>(3)</enum><text>evidence-based withdrawal management services.</text></paragraph></subsection><subsection id="HB58F79AF40364213964AA2781F7A2949" commented="no"><enum>(b)</enum><header>Residential substance abuse treatment for State prisoners</header><text>Section 1904(d) of title I of the Omnibus Crime Control and Safe Streets Act of 1968 (<external-xref legal-doc="usc" parsable-cite="usc/34/10424">34 U.S.C. 10424(d)</external-xref>) is amended—</text><paragraph id="H9FC3FFD8B0CC4796AF571B8F82747807" commented="no"><enum>(1)</enum><text>by striking <quote>means</quote> and inserting the following:</text><quoted-block style="OLC" id="H0CFBE15F6BAC443CB5D0E55EC0EE1970" display-inline="no-display-inline"><paragraph id="H33FDBBCCFEDA44E3B60B1A2F85C4328A" commented="no"><enum>(1)</enum><text display-inline="yes-display-inline">means</text></paragraph><after-quoted-block>; </after-quoted-block></quoted-block></paragraph><paragraph id="HE97CC28FF4564F41A662A072AAA925DB" commented="no"><enum>(2)</enum><text>by striking the period at the end and inserting <quote>; and</quote>; and</text></paragraph><paragraph id="H80848D76FA364721B5BDB9C1A8A26031" commented="no"><enum>(3)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" id="H4C7DECD4CB6546FBB75BEBE11DFCD2D5" display-inline="no-display-inline"><paragraph id="HDD3B4B8E7A9D490B8341F49CFE76B124" commented="no"><enum>(2)</enum><text display-inline="yes-display-inline">includes any drug approved by the Food and Drug Administration for the treatment of substance use disorder.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection></section></title></legis-body></bill> 

